Mach7’s turnaround is now showing up in the numbers, and the next chapter is about growth. That was the throughline of a wide-ranging investor webinar with Managing Director Teri Thomas, hosted by Wei Sim of Homodeus Research. Over 45 minutes, Teri walked through where the business stands after a year of deliberate reset and why she believes Mach7 is well positioned for the imaging market taking shape around it.
The full replay is below. Here are the themes that matter most for shareholders.
Watch the complete ~45-minute discussion and audience Q&A above.
A market moment that favors the prepared
The backdrop is a tailwind, not a headwind. The enterprise imaging IT market is worth roughly US$2.3 billion in 2025 and is forecast to reach about US$4.1 billion by 2030, a compound annual growth rate near 12 percent, with vendor-neutral archives among the fastest-growing segments (MarketsandMarkets, 2025).
At the same time, the people who read images are getting scarcer. The United States has roughly 41,000 radiologists, imaging volumes are climbing several percentage points a year, and workforce shortages have been named radiology’s biggest threat three years running (ACR / Neiman Health Policy Institute, 2026). Add the surge in artificial intelligence: more than 1,150 FDA-cleared AI algorithms now exist for radiology, out of roughly 1,500 across all of medicine (FDA AI device list, March 2026). As Teri put it, AI makes every image more valuable, which raises the need for organized, accessible data rather than lowering it.
The reset is visible in the shape of the business
Mach7 delivered positive operating cash flow in the second quarter and sustained it into the third, carries no debt, and reduced its cost base by around six percent as part of the reset. Teri described the sequence deliberately: a disciplined operating model and cost base first, then a rebuilt commercial engine, then a customer-aligned roadmap. That order, she argued, is what creates a durable foundation for profitable growth rather than growth funded by hope.
From archive to architecture
Mach7 was founded on the vendor-neutral archive and became known as the VNA vendor. Teri described the strategy now underway as a deliberate move, in her words, “from archive to architecture”: building on that base into a modular imaging system that health systems can extend one piece at a time. Flamingo is the expression of that shift. The first Flamingo module signed its first customer in fiscal 2026 and that customer is now live in production, with additional modules being validated alongside early-adopter customers through fiscal 2027.
The advantage Teri emphasized is modularity without disruption. Rather than a high-risk rip-and-replace, Mach7 can sit as the steady base while customers keep some existing systems in place and modernize gradually. Every new module is designed to save customers money, which matters to CFOs weighing cloud against on-premises storage and managing real cost pressure.
Built for the AI age by design
A recurring point: the value of a truly vendor-neutral archive lies in solving the data problem AI depends on. Many hospitals still have images locked in proprietary silos and inconsistent formats spread across hundreds of sources. Before AI can help at scale, that data has to be pulled together, organized, and made accessible. A neutral archive that ingests any image type from any source, rather than one limited to a single vendor’s hardware, is precisely that foundation.
The same logic applies to the tools built on top of that data. Getting an organization’s imaging data into a single, accessible, well-organized foundation is what enables modern applications to work reliably. The eUnity enterprise diagnostic viewer, which is FDA-cleared, gives clinicians a single, fast way to open many image types via a web link, supporting growth in teleradiology and cross-specialty access.
Leadership built for this stage
Teri’s background maps directly to where Mach7 is now. She spent 20 years at Epic, joining when it had fewer than 100 employees and staying through its growth into a global health IT company of more than 10,000 employees, then led a turnaround as CEO of ASX-listed Volpara. The common thread is a customer-success-led model she calls the Mach7 loop: earn customer trust, let customer advocacy open doors, reinvest in the product, and let the flywheel compound. Her operating mantra, borrowed from Epic, is that execution must equal reality: make careful commitments, then meet them.
Where FY27 is heading
Teri framed three priorities for the year ahead: shift from reset to growth by building pipeline through expanded marketing and stronger partnerships; complete the product shift from archive to a modular imaging system customers build on; and fund that growth from a position of strength, with the rigor of the do-good, have-fun, make-money discipline she brought to the leadership team. Underneath all of it is the mission she keeps returning to: faster access to the right images at the right moment, so care teams stay connected to the patient at the end of every workflow.
Watch the full webinar
The complete presentation and live Q&A are available in the replay above. For more on Mach7’s strategy and results, visit the investor section of our website.
Disclaimer
This post accompanies a Sharewise webinar featuring Teri Thomas and references comments made about Mach7 Technologies Limited (“M7T”). The views and statements expressed by Ms. Thomas are provided for general information only and were current as at the date of the recording.
Not financial product advice. The information regarding M7T is general in nature and is not financial product, investment advice, or a recommendation to acquire M7T securities. It has been prepared without taking into account the objectives, financial situation or needs of any person. Before making any investment decision, you should consider the appropriateness of the information having regard to your own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to your jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities.
Forward-looking statements. The webinar and this post may contain forward-looking statements, opinions and estimates about M7T that are based on assumptions and contingencies subject to change without notice. Such statements — including any projections, forecasts or estimates — are provided as a general guide only, should not be relied on as an indication or guarantee of future performance, and involve known and unknown risks and uncertainties, many of which are outside M7T’s control. Past performance is not necessarily a guide to future performance.
No offer. This post is not, and should not be considered as, an offer or invitation to acquire securities in M7T or any other financial product. The information remains subject to change without notice, and M7T assumes no obligation to update it. Unless otherwise stated, all dollar values are in Australian dollars (AUD$).